文献速递糖尿病

二甲双胍:历史回顾

Metformin: historical overview.
PubMed 文献 · Diabetologia · 2017-08-03

二甲双胍(dimethylbiguanide)已成为管理2型糖尿病的首选一线口服降糖药。其历史与欧洲传统草药山羊豆(Galega officinalis)相关,该植物富含胍类,1918年发现其可降低血糖。胍类衍生物(包括二甲双胍)被合成,1920至1930年代部分(非二甲双胍)用于治疗糖尿病,但因毒性和胰岛素普及而停用。1940年代在抗疟药研究中重新发现二甲双胍,临床试验中治疗流感时有时降低血糖。法国医生Jean Sterne于1957年首次报告二甲双胍治疗糖尿病。因效力不及其他降糖双胍类(苯乙双胍和丁双胍),二甲双胍关注有限,后者因乳酸酸中毒高风险在1970年代末普遍停用。二甲双胍前景 precarious,声誉因与其他双胍关联而受损,尽管存在明显差异。二甲双胍对抗胰岛素抵抗和解决成人起病高血糖且不增重或不增加低血糖风险的能力在欧洲逐渐获得认可,经过严格审查,二甲双胍于1995年进入美国。1998年英国前瞻性糖尿病研究(UKPDS)确定了二甲双胍的长期心血管获益,为采用二甲双胍作为2型糖尿病高血糖初始治疗提供了新理由。引入糖尿病治疗六十年后,二甲双胍已成为全球处方量最大的降糖药,并具有进一步治疗应用的潜力。

要点

  • 二甲双胍已成为管理2型糖尿病的首选一线口服降糖药。
  • 二甲双胍于1957年由法国医生Jean Sterne首次报告用于治疗糖尿病。
  • UKPDS于1998年确定二甲双胍的长期心血管获益。

核心结论

  • 二甲双胍已成为全球处方量最大的降糖药,并具有进一步治疗应用的潜力。

研究设计与样本

  • 本文为历史回顾,未报告系统检索范围或样本量。

主要发现

  • 1918年发现胍类可降低血糖。
  • 1920至1930年代,胍类衍生物(非二甲双胍)用于治疗糖尿病,但因毒性和胰岛素普及而停用。
  • 1940年代抗疟药研究中重新发现二甲双胍,临床试验中治疗流感时有时降低血糖。
  • 1957年Jean Sterne首次报告二甲双胍用于治疗糖尿病。
  • 苯乙双胍和丁双胍因乳酸酸中毒高风险在1970年代末普遍停用。

临床怎么用

  • 二甲双胍已成为管理2型糖尿病的首选一线口服降糖药。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metformin (dimethylbiguanide) has become the preferred first-line oral blood glucose-lowering agent to manage type 2 diabetes. Its history is linked to Galega officinalis (also known as goat's rue), a traditional herbal medicine in Europe, found to be rich in guanidine, which, in 1918, was shown to lower blood glucose. Guanidine derivatives, including metformin, were synthesised and some (not metformin) were used to treat diabetes in the 1920s and 1930s but were discontinued due to toxicity and the increased availability of insulin. Metformin was rediscovered in the search for antimalarial agents in the 1940s and, during clinical tests, proved useful to treat influenza when it sometimes lowered blood glucose. This property was pursued by the French physician Jean Sterne, who first reported the use of metformin to treat diabetes in 1957. However, metformin received limited attention as it was less potent than other glucose-lowering biguanides (phenformin and buformin), which were generally discontinued in the late 1970s due to high risk of lactic acidosis. Metformin's future was precarious, its reputation tarnished by association with other biguanides despite evident differences. The ability of metformin to counter insulin resistance and address adult-onset hyperglycaemia without weight gain or increased risk of hypoglycaemia gradually gathered credence in Europe, and after intensive scrutiny metformin was introduced into the USA in 1995. Long-term cardiovascular benefits of metformin were identified by the UK Prospective Diabetes Study (UKPDS) in 1998, providing a new rationale to adopt metformin as initial therapy to manage hyperglycaemia in type 2 diabetes. Sixty years after its introduction in diabetes treatment, metformin has become the most prescribed glucose-lowering medicine worldwide with the potential for further therapeutic applications.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Bailey CJ. Metformin: historical overview. Diabetologia. 2017. PMID: 28776081. doi:10.1007/s00125-017-4318-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。